Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The new module introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. This capability is expected to significantly reduce the time and effort required for bioinformatics tasks, allowing researchers to focus on interpreting results and advancing discoveries. By automating multi-omic analysis, ZetaOmics aims to enhance the reproducibility of research, a persistent challenge in biomedical science.
Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations. This move positions Lantern to generate new revenue streams from its AI platform, which is now commercially available as a subscription-based research platform for the global biomedical and drug development community. The company’s pipeline includes oncology candidates such as LP-184, LP-284, and LP-300, and it operates an AI Center of Excellence in Bengaluru, India, with headquarters in Dallas, Texas.
The launch of ZetaOmics represents a strategic shift for Lantern Pharma, leveraging its proprietary RADR platform and AI expertise to offer tools that can accelerate cancer research across institutions. By providing an autonomous computational biologist, the platform could help smaller labs and organizations access advanced bioinformatics capabilities without needing extensive in-house expertise. This democratization of multi-omic analysis may lead to faster identification of biomarkers and therapeutic targets, ultimately benefiting patients through more efficient drug development.
For the broader industry, ZetaOmics underscores the growing integration of AI in precision oncology. As computational biology becomes more automated, researchers can handle larger datasets and more complex analyses, potentially uncovering insights that were previously unattainable. The platform’s focus on audit trails and publication-quality outputs also addresses concerns about reproducibility in academic and pharmaceutical research. Lantern’s move to offer this commercially suggests that AI-driven drug discovery platforms are evolving into standalone products, creating new business models beyond traditional drug development.
Investors and stakeholders can access the full press release at https://ibn.fm/9sIIl. For more information about Lantern Pharma, visit the company’s newsroom at https://ibn.fm/LTRN.
